Clinical failures in the pharmaceutical sector frequently trigger nervy departures by investors. Following back-to-back disappointing study results, Novartis shares suffered a double-digit decline, an extreme move for a blue-chip company. This negative news originating from Basel dragged the Swiss benchmark index heavily into negative territory, reigniting discussions regarding portfolio concentration risks and the overall utility of the Swiss Market Index. Roche, led by Thomas Schinecker, Novartis under Vas Narasimhan, and Nestlé headed by Philipp Navratil, collectively account for 47.4 percent of the benchmark.
Institutional investors bound by regulations prohibiting investments in highly concentrated indices often turn to alternatives. The Swiss Leader Index was designed for such mandates, capping the four largest constituents at nine percent each, representing half of the maximum weighting permitted in the benchmark index. Although the alternative index outperformed the main gauge between 2019 and 2025 by delivering a 96 percent return that beat the primary index by 8 percent, market dynamics shifted in 2026. According to Christoph Sax, chief investment officer at VZ VermögensZentrum, the primary index has outpaced both the alternative gauge and the broader Swiss Performance Index since the start of the year despite the correction in Novartis. This relative strength is supported by positive momentum among global pharmaceutical names, a valuation recovery at Nestlé from depressed levels, and robust gains by UBS.
Switzerland is not alone in high market concentration. In Denmark, the OMX Copenhagen 25 Index sees the pharmaceutical giant Novo Nordisk, logistics provider DSV, Danske Bank, and wind energy firm Vestas command a nearly identical 47.1 percent share. Within the Netherlands, Shell, Unilever, and semiconductor equipment manufacturer ASML represent 42.3 percent of the market capitalisation in the AEX Index. Taiwan's Taiex features an even starker dominance, where TSMC alone holds a 41.6 percent weighting. South Korea's Kospi displays a similar technology-heavy profile, with Samsung Electronics and SK Hynix claiming 48.2 percent of the measure. Technology concentration is also prominent in the United States. Within the S&P 500, the three largest corporations out of 0.6 percent of all index participants hold a 21 percent weighting. Thomas Heller, chief investment officer at Frankfurter Bankgesellschaft, notes that from this perspective, the American gauge is actually far more concentrated than the Swiss equivalent.
Schwyz Cantonal Bank points out that benchmarks are formulated to reflect market movements rather than to serve as ready-made investment portfolios. This distinction is most apparent in the Dow Jones Industrial Average, which weighs components by share price. Under a matching construction methodology in Switzerland, registered shares of Lindt & Sprüngli would carry an index weighting roughly 1,100 times greater than Nestlé, despite Nestlé possessing a market capitalisation approximately ten times larger than Lindt & Sprüngli.
Christoph Sax estimates that the roughly 1,300 Swiss pension funds hold approximately 60 billion francs out of a total 1,220 billion invested in Roche, Novartis, and Nestlé, representing a tangible concentration risk. Nevertheless, these entities maintain international and broadly diversified allocations, which dilutes the overall portfolio impact of domestic large-cap equities.
